SNCA and Parkinson disease: A limitation of the initial study was that mice were treated with the shRNA-MC RVG-exosomes therapy before the development of alpha-synuclein pathology; however, Parkinson’s disease diagnosis is based on the presence of classical motor symptoms, and at this point significant disease pathology and Parkinson’s disease progression already exist [33].